EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

PURPOSE: To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting agent, monomethyl auristatin E, to cells that express Nectin-4. METHODS: EV-101 is a phase I dose escalation/expansio...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Rosenberg, Jonathan, Sridhar, Srikala S., Zhang, Jingsong, Smith, David, Ruether, Dean, Flaig, Thomas W., Baranda, Joaquina, Lang, Joshua, Plimack, Elizabeth R., Sangha, Randeep, Heath, Elisabeth I., Merchan, Jamie, Quinn, David I., Srinivas, Sandy, Milowsky, Matthew, Wu, Chunzhang, Gartner, Elaina M., Zuo, Peiying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2020
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106979/
https://ncbi.nlm.nih.gov/pubmed/32031899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02044
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker